Compare Garmin Ltd. (GRMN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Smith & Nephew plc — how do they compare? Garmin Ltd. trades at $271.28 (market cap $53.26B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: Garmin Ltd. is far larger — about 4.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Smith & Nephew plc for 120 Days on average.
| GRMN | SNN | |
|---|---|---|
Market Cap | $53.26B | $11.31B |
Volume | 529,054 | 1,050,005 |
Sector | Technology | Health |
52-Week High | $313.16 | $37.17 |
52-Week Low | $187.10 | $26.42 |
Typical Hold Time | 83 Days | 120 Days |
Enterprise Value | $50.77B | $14.35B |
Dividend Yield | 1.52% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 3.86% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.81 beating estimates of $2.30. Revenue growth remains robust, rising from $4.9B in 2022 to $7.25B in 2025, with net income margins above 20%. Recent positive developments include multiple product awards and new feature rollouts across marine, automotive, and fitness segments.
Garmin presents a compelling investment case with strong profitability and consistent execution, though near-term technical pressure and cautious analyst sentiment (71% hold rating) suggest potential volatility. The consensus price target of $320.25 implies 19% upside, but investors should monitor competitive pressures in the wearable tech space and macroeconomic factors affecting consumer discretionary spending.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
